Acute Exacerbation of COPD: Evidence‑Based Management Guidelines

Initial Assessment & Differential Diagnosis

Before confirming an acute COPD exacerbation, actively rule out acute coronary syndrome, worsening heart failure, pulmonary embolism, and pneumonia because these conditions require distinct treatment pathways. 1

Mild exacerbation – can be managed with short‑acting bronchodilators alone. 3
Moderate exacerbation – requires short‑acting bronchodilators plus antibiotics and/or oral systemic corticosteroids. 3
Severe exacerbation – mandates hospitalization or emergency‑department evaluation and may involve acute respiratory failure. 3

Initiate short‑acting inhaled β₂‑agonists (e.g., albuterol) with or without short‑acting anticholinergics (e.g., ipratropium) for every acute COPD exacerbation. Strong recommendation. 3
Do not use methylxanthines (theophylline) in acute exacerbations; they provide no clinical benefit and increase adverse events. Strong recommendation. 3

Systemic corticosteroids improve FEV₁, oxygenation, shorten recovery time, and reduce hospital length of stay. Strong recommendation, high‑quality evidence. 3
Early administration of systemic corticosteroids in moderate‑to‑severe exacerbations improves outcomes; delaying therapy worsens clinical parameters. Strong recommendation. 2

Antibiotics should be prescribed only when bacterial infection is suspected (e.g., purulent sputum or increased sputum volume). Strong recommendation. 1
When indicated, antibiotics shorten recovery time, lower the risk of early relapse, and reduce hospitalization duration. Strong recommendation. 3

Target oxygenation to maintain PaO₂ ≥ 60 mmHg (≈ 8 kPa) or SpO₂ 88–92% to avoid hypoxia while preventing CO₂ retention. Strong recommendation. 1
Avoid excessive oxygen in patients at risk for hypercapnia, as over‑oxygenation can worsen CO₂ retention. Strong recommendation. 2

NIV is the first‑line ventilatory support for acute respiratory failure in COPD exacerbations. Strong recommendation, robust mortality‑reduction evidence. 3
Early initiation of NIV before severe acidosis (pH < 7.30) reduces mortality and the need for invasive intubation. Strong recommendation. 1

Initiate maintenance long‑acting bronchodilator therapy (LAMA or LAMA + LABA) before hospital discharge to lower the risk of recurrent exacerbations. Strong recommendation. 3
Implement evidence‑based preventive measures: influenza and pneumococcal vaccination, smoking cessation counseling, and inhaler technique review. Strong recommendation. 1
Arrange pulmonary rehabilitation to start within three weeks after discharge (not during the inpatient stay). Strong recommendation. 1

The majority of patients experience symptom resolution within 7–10 days after an acute exacerbation. Strong recommendation. 3

Delaying systemic corticosteroids in moderate‑to‑severe exacerbations worsens outcomes; early use is essential. 2
Using methylxanthines increases adverse events without clear benefit; they should be avoided. 3
Over‑oxygenating patients prone to CO₂ retention can exacerbate hypercapnia; titrate to SpO₂ 88–92%. 2
Missing alternative diagnoses (cardiac, thromboembolic, infectious) leads to inappropriate COPD‑focused treatment; always consider these differentials. 1